Therapeutic Potentials of Inhibition of Jumonji C Domain - containing Demethylases in Acute Myeloid Leukemia

Creative Commons License

Koca D., Hastar N., Engur S., Kiraz Y., Ulu G. T., Cekdemir D., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.1, ss.5-12, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4274/tjh.galenos.2019.2019.0083
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.5-12
  • Anahtar Kelimeler: Acute myeloid leukemia, Methylstat, Jumonji C domain, Histone methylation, HISTONE DEMETHYLASES, BONE-MARROW, CANCER, METABOLISM
  • Anadolu Üniversitesi Adresli: Evet

Özet

Objective: Acute myeloid leukemia (AML) is a complex disease affected by both genetic and epigenetic factors. Histone methylation and demethylation are types of epigenetic modification in chromatin remodeling and gene expression. Abnormal expression of histone demethylases is indicated in many types of cancer including AML Although many commercial drugs are available to treat AML, an absolute cure has not been discovered yet. However, inhibition of demethylases could be a potential cure for AML Methylstat is a chemical agent that inhibits the Jumonji C domain-containing demethylases.